Patents by Inventor Olorunseun O. Ogunwobi

Olorunseun O. Ogunwobi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DESTABILIZED ARE 3'UTRs AS THERAPEUTICS FOR CANCER
    Publication number: 20230331818
    Abstract: A nucleotide that encodes for a destabilized RNA that corresponds to ERBB2 (erythroblastic oncogene B) or MYC oncogenes. The destabilization occurs in an adenylate-uridylate rich element (ARE) stabilizing motif. Without wishing to be bound to any particular theory, changing the stabilizing motifs of ERBB2 and MYC to destabilization motifs is believed to lead to the rapid degradation of their transcripts. Thus, in turn, renders the composition useful as a therapeutic for cancer.
    Type: Application
    Filed: March 1, 2023
    Publication date: October 19, 2023
    Inventors: Olorunseun O. Ogunwobi, Chidiebere U. Awah, Kevin Struhl
  • Plasmid vector for expressing a PVT1 exon and method for constructing standard curve therefor
    Patent number: 11225666
    Abstract: A method for cloning an exon into a plasmid vector. Exons related to prostate cancer (PVT1 exon 9, PVT1 exon 4A or PVT1 exon 4B) and miRNAs (miR-1205 or miR-1207-3p) are transformed into the plasmid vector. The cloned exons or miRNAs are linearized and their concentrations quantified. Serial dilutions in conjunction with spectroscopy permit the construction of a standard curve that permits absolute quantification of the exons or miRNAs in a biological sample from a patient.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: January 18, 2022
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Gargi Pal
  • Methods of using PVT1 exon 9 to diagnose and treat prostate cancer
    Patent number: 10947535
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: March 16, 2021
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • METHODS OF USING PVT1 EXON 9 TO DIAGNOSE AND TREAT PROSTATE CANCER
    Publication number: 20190382768
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Application
    Filed: July 5, 2019
    Publication date: December 19, 2019
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • PLASMID VECTOR FOR EXPRESSING A PVT1 EXON AND METHOD FOR CONSTRUCTING STANDARD CURVE THEREFOR
    Publication number: 20190284565
    Abstract: A method for cloning an exon into a plasmid vector. Exons related to prostate cancer (PVT1 exon 9, PVT1 exon 4A or PVT1 exon 4B) and miRNAs (miR-1205 or miR-1207-3p) are transformed into the plasmid vector. The cloned exons or miRNAs are linearized and their concentrations quantified. Serial dilutions in conjunction with spectroscopy permit the construction of a standard curve that permits absolute quantification of the exons or miRNAs in a biological sample from a patient.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 19, 2019
    Inventors: Olorunseun O. Ogunwobi, Gargi Pal
  • Methods of using PVT1 exon 9 to diagnose and treat prostate cancer
    Patent number: 10344283
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 9, 2019
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • miRNAs USEFUL FOR IDENTIFYING TARGETS ASSOCIATED WITH CANCER
    Publication number: 20190085330
    Abstract: Several miRNAs are described that are useful in diagnosing and treating prostate cancer, or pancreatic cancer. The miRNAs bind with targets that are associated with prostate cancer or pancreatic cancer. This permits the identification of those targets as well as a treatment methodology for prostate cancer.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 21, 2019
    Inventors: Olorunseun O. Ogunwobi, Dibash K. Das
  • miRNAs useful for identifying targets associated with cancer
    Patent number: 10138481
    Abstract: Several miRNAs are described that are useful in diagnosing and treating prostate cancer, or pancreatic cancer. The miRNAs bind with targets that are associated with prostate cancer or pancreatic cancer. This permits the identification of those targets as well as a treatment methodology for prostate cancer.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: November 27, 2018
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Dibash K. Das
  • METHODS OF USING PVT1 EXON 9 TO DIAGNOSE AND TREAT PROSTATE CANCER
    Publication number: 20180080027
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 22, 2018
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • Methods of using PVT1 exon 9 to diagnose and treat prostate cancer
    Patent number: 9845472
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: December 19, 2017
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • METHODS OF USING PVT1 EXON 9 TO DIAGNOSE AND TREAT PROSTATE CANCER
    Publication number: 20170130230
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Application
    Filed: November 7, 2016
    Publication date: May 11, 2017
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • miRNAs USEFUL FOR IDENTIFYING TARGETS ASSOCIATED WITH CANCER
    Publication number: 20170121711
    Abstract: Several miRNAs are described that are useful in diagnosing and treating prostate cancer, or pancreatic cancer. The miRNAs bind with targets that are associated with prostate cancer or pancreatic cancer. This permits the identification of those targets as well as a treatment methodology for prostate cancer.
    Type: Application
    Filed: October 31, 2016
    Publication date: May 4, 2017
    Inventors: Olorunseun O. Ogunwobi, Dibash K. Das